Prostate Cancer

In an interview with Peers & Perspectives in Oncology, Rana McKay, MD, explains how an AI model can affect the disparities faced by racial minority groups and the wider adoption of AI in the prostate cancer space.

Enzalutamide is the first and only androgen receptor signaling inhibitor approved by the FDA in this intent-to-treat population.

In patients with metastatic castration-resistant prostate cancer of the adenocarcinoma phenotype, the combination of BXCL701 and pembrolizumab led to a median overall survival of 15.5 months.

In a subgroup analysis of the phase 3 EMBARK study, enzalutamide alone or with leuprolide acetate improved metastatic-free survival in men with high-risk prostate cancer following radiotherapy.

A discussion on streamlining patient care processes between urologists and medical oncologists while maintaining treatment continuity and minimizing disruptions for patients with prostate cancer.

Experts share insights into collaborative relay strategies between urologists and medical oncologists that ensure smooth handoffs and continued care for patients with prostate cancer receiving combination therapies.

The investigational agent is undergoing evaluation in a phase 1/2 trial for the treatment of relapsed or refractory metastatic castration-resistant prostate cancer resistant to androgen receptor pathway inhibitors.

David Morris, MD, FACS, and Benjamin Garmezy, MD, discuss treatment options, including ARPIs like enzalutamide and darolutamide, in nmCRPC, emphasizing the importance of personalized approaches for patient quality of life and outcome improvement.

ARX517 showed early efficacy in patients with metastatic castration-resistant prostate cancer in the phase 1/2 APEX-01 study.

Insight into the expanding landscape of hormone therapies, including androgen receptor inhibitors and biosynthesis inhibitors, and their diverse applications in prostate cancer treatment.

Key opinion leader Benjamin Garmezy, MD, discusses the shifting landscape of prostate cancer management, the importance of identifying lethal cases, and the challenges in risk stratification and prognosis.

Adding niraparib to abiraterone acetate and prednisone was associated with an overall survival benefit compared with AAP alone in patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer.

The addition of pembrolizumab to enzalutamide did not improve survival compared with enzalutamide alone in patients with metastatic castration-resistant prostate cancer.

Adding 177Lu-PSMA-617 to enzalutamide improved prostate-specific antigen progression-free survival in patients with metastatic castration-resistant prostate cancer.

Expert perspectives on the importance of forging collaborative relationships between urologists and medical oncologists in prostate cancer care, focusing on shared decision-making and patient-centric approaches.

Join David Morris, MD, FACS, and Benjamin Garmezy, MD, as they discuss their collaborative approach to treating advanced prostate cancer and the benefits it brings to patient care.

In an interview with Targeted Oncology, Rohan Garje, MD, discussed current treatment options for patients with prostate cancer and the role of PARP inhibitors.

During a Targeted Oncology™ Case-Based Roundtable™ event, Benjamin Garmezy, MD, discussed trial data that guides when to use cabazitaxel for patients with metastatic castration-resistant prostate cancer.

In a phase 2 trial, BXCL701 and pembrolizumab showed a significant increase in median overall survival time for patients with small cell neuroendocrine prostate cancer.

Data from the PROpel study support the FDA’s approval of olaparib plus abiraterone for patients with metastatic castration-resistant prostate cancer.

The disruption of the fine-tuned androgen receptor protein multivalent interactions might contribute to AR-related human pathologies.

Investigators presented results from new studies at the 2023 ASTRO Meeting. The data showcase a new assay’s performance in predicting metastasis-free survival and distant metastasis.

Additional findings from the phase 3 LIGHTHOUSE trial support flotufolastat F 18 injection and its approval in the prostate cancer space.

The phase 1/2 trial is evaluating 64Cu/67Cu SAR-Bombesin for diagnosis and treatment of castrate resistant prostate cancer.